<scp>SARS‐CoV</scp>‐2 infection in patients with β‐thalassemia: Experience from <scp>Lebanon</scp>

Bou‐Fakhredin, Rayan; Daadaa, Hisham; Koussa, Suzanne; Nasr, Therese Abou; Noun, Peter; Taher, Ali T.

doi:10.1002/ajh.26211

Cited by 3 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, 60% (18/30) of the patients with thalassemia and COVID-19 were asymptomatic akin to the Lebanese study by Bou-Fakhredin et al [ 17 ]. However, unlike their study, all the symptomatic cases in our study population were mild, and none required oxygen support or hospitalization.…”

Section: Discussionsupporting

confidence: 74%

See 1 more Smart Citation

COVID-19 Antibody Response in Patients with Thalassemia

Kumari¹,

Gomber²,

Dewan³

et al. 2023

Cureus

View full text Add to dashboard Cite

Background The coronavirus disease 2019 (COVID-19) can severely affect people with comorbidities such as those with diabetes, hypertension, chronic lung disease, cancer, and hemoglobinopathies. Studies assessing the clinical characteristics and immune response to COVID-19 infection in patients with thalassemia are limited. Objectives The primary objective of the study was to study the clinical pattern and the immunoglobulin G (IgG) antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with transfusion-dependent thalassemia (TDT) compared to patients without thalassemia. The secondary objective wasto study the relationship of COVID-19 severity with IgG antibody titers. Setting, Design, and Participants This case-control study was conducted at a tertiary care hospital between January 2021 and August 2022. A total of 30 patients with TDT (mean age: 12.7 years, SD: 4.7) and 30 patients without thalassemia (mean age: 13.9 years, SD: 7) who tested positive for COVID-19 in the preceding six weeks were recruited. Methods Serum samples from the cases and controls were collected after 6, 12, and 24 weeks of COVID-19 infection for IgG antibody estimation using chemiluminescent immunoassay. Outcome variables The primary variable was comparative analysis of antibody levels and clinical profile of COVID-19 in cases and controls. The secondaryvariable was association of the severity of COVID-19 with the antibody titers produced. Results Symptomatic individuals among cases (n=12) were significantly lesser than controls (n=22) (p=0.009). The median IgG titers of cases and controls were comparable at six weeks (p=0.40), but the titers were significantly lower for cases at 12 weeks (p=0.011) and 24 weeks (p=0.006). There was significant fall in titers from 6 to 12 and 24 weeks in both the groups. The titers were not affected by COVID-19 severity and pre-existing comorbidities. Conclusion Patients with TDT manifest with mild or asymptomatic COVID-19 and mount a comparable IgG antibody response to COVID-19 akin to controls. However, this serological response could not sustain over three to six months advocating the need for protection through vaccination.

show abstract

Section: Discussionsupporting

confidence: 74%

“…The studies conducted on thalassemia patients with COVID-19 are sparse [17][18][19][20][21] (Table 3), and to the best of our knowledge, this is a pioneer case-control study to assess the IgG antibody response of TDT patients post-COVID-19 infection. No deaths reported, no correlation between blood group and clinical course of disease.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Antibody Response in Patients with Thalassemia

Kumari¹,

Gomber²,

Dewan³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Although previous studies do not indicate a greater severity of Covid-19 in β-thalassemia patients, it is necessary to limit infection risk, not only for virus pathogenic effects, but to avoid in symptomatic patients the interruption of iron chelation therapy [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients

Anastasi

Marziali

Preziosi

et al. 2022

Microbes and Infection

View full text Add to dashboard Cite

“…Ineffective erythropoiesis in patients with nontransfusion-dependent β-thalassemia (NTDT) leads to chronic anemia that does not necessarily require lifelong transfusion therapy for survival. 1 Nonetheless, chronic anemia in these patients is associated with significant morbidity, especially in patients with a hemoglobin level lower than 10 g/dL. 2 Hemoglobin variations greater than 1 g/dL have also been shown to modify morbidity risk.…”

Section: Risk Of Mortality From Anemia and Iron Overload In Nontransf...mentioning

confidence: 99%

“…Data from Lebanon confirmed a role of underlying comorbidities on COVID-19 severity, but no deaths among a cohort of thalassemia patients. 1 Patients with sickle cell disease (SCD) displayed a broad range of severity after SARS-CoV-2 infection, spanning from a favorable outcome unless preexisting comorbidities (UK cohort) 2 to high case mortality in US. 3 History of pain, heart, lung, and renal comorbidities was identified as risk factors of worse COVID-19 outcomes by the US SECURE-SCD Registry.…”

mentioning

confidence: 99%